AstraZeneca PLC Q3 FY2024 earnings call

Management Statement and Operational Highlights

• Financial Performance: Total revenue increased 19% in the first nine months. Product sales rose 19%, alliance revenue grew 50% to $1.5 billion. Core EPS grew 11%. Operating activities showed a $989 million net cash inflow improvement.
• Pipeline Readouts: Multiple Phase 3 results were delivered, including LAURA expanding Tagrisso's reach, DESTINY-Breast06 breaking ground for HER2, and Imfinzi showing positive readouts for small cell lung cancer and bladder cancer. Also, KOMET and WAYPOINT had potential for new indications.
• Investments: Announced $3.5 billion investment in U.S. manufacturing and R&D to strengthen presence in the key market.
• China Update: Committed to presence in China, supporting employees, with limited info on investigations but focusing on Q3 performance and emphasizing ongoing operations and pipeline development in the country.

Segment Performance

• Oncology: Total revenues grew 22% in the first nine months to $16 billion. Key medicines like Tagrisso, Calquence, Imfinzi, Lynparza, and HER2 products showed strong growth. For example, Tagrisso expanded in early-stage lung cancer via LAURA, Calquence advanced in mantle cell lymphoma, and Lynparza was the leading PARP inhibitor globally.
• BioPharmaceuticals: Delivered total revenue of $15.9 billion in the first nine months, up 20%. CVRM (Farxiga) saw 27% growth, R&I (Tezspire, Breztri) had 29% growth, and V&I (Beyfortus) returned to growth with 49% increase. Wainua, a medicine for ATTR polyneuropathy, grew 44% sequentially.
• Rare Disease: Grew 14% to $6.4 billion in the first nine months, driven by neurology indications and new launches like Ultomiris (35% revenue growth) and Koselugo (39% growth).

Guidance

• Upgraded full-year 2024 guidance, expecting total revenue and core EPS to increase by high teens percentages at constant exchange rates, up from prior mid-teens expectations.
• Confident in 2025 outlook driven by indication expansion opportunities, continued global demand for medicines, and a catalyst-rich pipeline period ahead.

Risks

• China Investigations: Uncertainty around impact on business due to ongoing investigations, with limited visibility on details and potential negative implications, though company remains committed to presence in China.
• Regulatory and Market Risks: Potential headwinds from initiatives like IRA (Inflation Reduction Act) and VBP (Volume-Based Purchasing) in China, as well as regulatory decisions affecting pipeline products like Dato-DXd.